Summary: We developed a non-competitive, enzyme-linked, immunosorbent assay (ELISA) for the quantitation of lipoprotein lipase (LPL) in human postheparin plasma using affinity-purified antihuman milk lipoprotein lipase antibodies produced in chicken eggs and a monoclonal antibody directed against human lipoprotein lipase. We compared our ELISA method with a commercially available sandwich-enzyme immunoassay (Markit-F LPL EIA Kit, Dainippon Pharmaceutical Co, Ltd. Osaka, Japan). The reference values for lipoprotein lipase catalytic activity concentration and mass concentration in healthy Finns were determined. Lipoprotein lipase activity concentration (mean ± SD) was 297 ± 112U/1 in women, and mass concentration as measured by the ELISA method was 1058 ± 367 g/l. The corresponding values for men were 247 ± 97 U/l and 815 ± 207 g/l, respectively. Across the whole concentration range of the ELISA method, the control samples' intra-and inter-assay coefficients of variation (CV) were 5.1% and 6.5%, respectively. The correlation between the ELISA and EIA methods was good, r = +0.81. The importance of the correct standardisation of immunoassays is discussed.
Introduction
Lipoprotein lipase (EC 3.1.1.34) plays a central role in lipoprotein metabolism by hydrolysing both dietary and endogenous triacylglycerols transported in chylomicrons and VLDL particles (1) (2) (3) . Upon hydrolysis, fatty acids are liberated for use in adipose and muscle tissues. Lipoprotein lipase protein is mainly synthesised in adipose tissue, muscles, and lactating mammary glands (4) . The mature protein is secreted from parenchymal cells and transported to capillaries, where lipoprotein lipase is bound to glycosaminoglycan components of the capillary endothelium (5, 6) .
Lipoprotein lipase can be released into the circulation by intravenous injection of heparin, which enables the lipoprotein lipase to be measured in postheparin plasma. An antiserum inhibition method using glycerol tri [l-C 14 ]oleate as a substrate was the principle method used to measure lipoprotein lipase activity concentration (7) . Many immunological approaches for the quantitation of lipoprotein lipase mass concentration in plasma using both poly-and monoclonal antibodies have been reported (8) (9) (10) (11) (12) (13) (14) (15) . At present, only one commercial kit for the quantitation of lipoprotein lipase mass concentration in plasma is available (Markit-F LPL EIA Kit, Dainippon Pharmaceutical Co, Ltd. Osaka, Japan) (15) .
In metabolic studies on patients with lipid disorders, the analysis of lipoprotein lipase activity concentration and mass concentration are important diagnostic measurements to estimate whether or not the lipid abnormalities result from a defect in the lipoprotein lipase protein structure. In investigating the functional abnormalities of lipoprotein lipase enzyme in genetic dyslipidaemic disorders, selective measurements of activity concentration and mass concentration have provided valuable data on the synthesis and secretion of lipoprotein lipase protein in cell culture systems (16, 17) .
In this report we describe the immunisation protocol for chickens, the purification of polyclonal anti-human lipoprotein lipase antibodies in chicken eggs, and the development of an enzyme-linked immuno-sorbent assay (ELISA), a non-competitive sandwich method for quantitation of lipoprotein lipase mass concentration in postheparin plasma. The present method developed is an extension to our previously described lipoprotein lipase ELISA assay (14) . In this paper we focussed on the methodological details. We also compared our ELISA method with a commercial, one-step sandwich EIA (15) , and determined reference values for postheparin plasma lipoprotein lipase mass concentration and activity concentration in healthy Finns. This study confirms the need for international reference materials to be compiled among laboratories and the importance of the correct standardisation of immunoassays.
Methods

Purification of human milk lipoprotein lipase
Step 1. Acetone-ether powder of lipoprotein lipase Human milk was obtained from the Human Milk Bank, University Hospital of Helsinki, and was immediately frozen at -20 °C. After thawing, the milk was centrifuged at 10000g for 30 min, at + 4 °C. The fat cake was separated and delipidated according to the protocol described by Zeclmer (17), using a sequential delipidation with cold acetone and diethyl ether. The acetone-ether powder was dried under nitrogen and stored at -20 °C before use.
Step 2. Heparin-Sepharose chromatography Four grams of acetone-ether powder were extracted for 2 h at + 4 °C with 60 ml of 0.1 mol/1 NaCl, 0.05 mol/1 NHUOH/NI^Cl (pH 8.5), containing 2 g/1 Triton N-101, 2000 IU aprotinin and 360 μg leupeptin. The mixture was centrifuged at 10 000 g for 30 min at + 4°C. Glycerol, 100 g/1, and solid NaCl were added to the supernatant to reach the final concentration of 0.35 mol/1 NaCl. A heparin-Sepharose column (28 X 60 mm, 48 ml) (Pharmacia, Uppsala, Sweden) was equilibrated with 0.35 mol/1 NaCl, 100 g/1 glycerol, 5 mmol/1 sodium barbital, pH 7.4 containing 0.5 g/1 EDTA and 0.5 g/1 NaN 3 . The acetone-ether extract was applied to the column at a flow rate of 1 ml/min. The column was washed in 1 mol/1 NaCl, 100 g/1 glycerol, 5 mmol/1 sodium barbital, pH 7.4 containing 0.5 g/1 EDTA and NaN 3 until the UV-absorption (A 28 o) of the eluate reached the baseline. Lipoprotein lipase was eluted from the heparin-Sepharose column with a buffer of 2 mol/1 NaCl, 100 g/1 glycerol, 5 mmol/1 sodium barbital, pH 7.4 containing 0.5 g/1 EDTA and NaN 3 , and 1 g/1 Triton N-101. Lipoprotein lipase activity was measured (7) , and the active fractions were combined.
Step 3. m-Aminophenylboronic acid (PEA) agarose affinity chromatography A PBA-agarose column (28 mm X 30 mm, 24 ml) (Sigma, St. Louis, USA) was packed and equilibrated with 10 mmol/1 phosphate, 100 g/1 glycerol, l mol/1 NaCl, pH 7.5 containing 2 g/1 Triton N-101 and 1 mmol/1 EDTA. The pool of combined active fractions from the heparin-Sepharose column was applied onto the PBAcolumn with a flow rate of 1 ml/min. Lipoprotein lipase activity was quantitatively bound to the column as no lipoprotein lipase activity could be measured in either the eluate or in the wash fractions. Lipoprotein lipase protein was eluted with 10 mmol/1 phosphate, 1 mol/1 NaCl, 200 g/1 glycerol, 2 g/1 Triton N-101, 0.3 mol/1 sorbitol, pH 10, containing 1 mmol/1 EDTA and 0.1 g/1 NaN 3 (19) . The fractions with lipoprotein lipase activity were pooled and stored at -20 °C.
Step 4. Preparative gel electrophoresis Twenty ml aliquot of /w-aminophenylboronic acid pool of lipoprotein lipase-active fractions were precipitated using chloroformmethanol (20) , and electrophoresis was performed on a homogenous 125 g/1 SDS-polyacrylamide gel (SDS-PAGE). The protein band was visualised with Serva blue, and the fraction corresponding to a lipoprotein lipase molecular mass was dissected out and eluted overnight with 0.1 mol/1 Tris-HCl, 0.1 mmol/1 SDS, pH 8.8 buffer in a tube roller at room temperature.
The purity of lipoprotein lipase
Samples from each purification step were analysed on a 125 g/1 SDS-PAGE gel and stained with Coomassie staining, as shown in figure 1 A. The same samples were also tested for purity with Western blot analysis using monoclonal antihuman lipoprotein lipase antibody (Oncogene Science, New York, USA) ( fig. IB) .
Other methods .SDS-PAGE was run as described by Laemmli (21) . Western blotting was performed according to Towbin et al. (22) . Protein concentration was determined with the Lowry method (23) using a human serum albumin as a standard.
Production of polyclonal chicken egg antibodies against lipoprotein lipase Leghorn hens were immunised at the age of 25 weeks with an initial dose of 50 μg of lipoprotein lipase protein emulsified in complete Freund's adjuvant. The animals were injected intramuscularly, followed every second week by booster injections of 50 μg lipoprotein lipase protein in incomplete adjuvant. The eggs began to be collected one month after the first antigen injection.
• ι Purification of polyclonal antihuman lipoprotein lipase antibodies from eggs The purification of egg immunoglobulins was carried out as described by Jensenius et al. (24) . Briefly, the yolk was separated from the white, diluted in Tris buffered saline (1 :4), and centrifuged at 2000 g for 20 min at room temperature. The supernatant was mixed with 150 g/1 Dextran sulphate, 1 mol/1 CaCl 2 in Tris buffered saline, left to stand at room temperature for 30 min, and centrifuged at 2000 g for 20 rain. The proteins in the supernatant were precipitated overnight with ammonium sulphate (300 g/1) at room temperature. The protein pellet was extracted with 15 mrnol/1 Tris-HCl, 1 mol/1 urea, pH 8.0, and solubilised proteins were run through a DEAE-Affi-Gel Blue® column (Bio-Rad, Hercules, California, USA) at a flow rate of 1.0 ml/min. After washing, the bound antibodies were eluted with 15 mmol/1 Tris-HCl, 1 mol/1 urea, pH 8.0. The protein in elution fractions was monitored at A 280 .
Affinity-purification of chicken antihuman lipoprotein lipase antibodies A 1.0 g cyanogen bromide (CNBr)-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) column was prepared according to the manufacturer's instructions (25) . Semi-purified human milk lipoprotein lipase protein (1 mg) was covalentiy coupled with the gel matrix. Tlie final lipoprotein lipase affinity gel was packed into a 4 ml column.
An aliquot of 5 ml from DEAE-Affi-Gel Blue® chromatography pool was applied through the affinity column at a flow rate of 0.5 ml/min. The column was washed with phosphate buffered saline until the A 280 reached the baseline. Immunoglobulins were released with 0.1 mol/1 glycine, pH 2.5. The eluted fractions were immediately neutralised with l mol/1 Tris-HCl, pH 8.5. The A 280 peak fractions were pooled. Immunoglobulins were dialysed against phosphate buffered saline and stored at -20 °C.
ELISA for quantitation of lipoprotein lipase
A polyclonal, affinity-purified, antihuman lipoprotein lipase antibody of chickens (5 mg/1 in carbonate buffer, pH 9.6) was bound to microtitre plates by incubation for 4 h at -1-25 °C. The plates were washed 6 times with phosphate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20 and blocked with phosphate buffered saline, 10 g/1 bovine serum albumin, 0.5 g/1 Tween-20 for 2 h at -f 37 °C. After six washes, lipoprotein lipase standards (66, 33, 16.5, 8.25, 4.1, 2.1, 1.0, and 0.5 μg/l) and lipoprotein lipase samples were added (diluted in phosphate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20) and incubated at + 4 °C for a minimum of 16 h. The wells were washed six times and monoclonal antihuman-lipoprotein lipase antibody (Oncogene Science, New York, USA) was added in a 1 : 10000 dilution in phosphate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20 and incubated for 3 hours at room temperature. After six washes, biotinylated affinity-purified rabbit anti-mouse antibody (Dako A/S, Glostrup, Denmark, 1 : 4000 in phosphate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20) was added, and the reaction proceeded for 2 h at + 37 °C. After six washes streptavidin-peroxidase was added (Amersham, Amersham, U. K., 1 : 2000 in phosphate buffered saline, 1 g/1 bovine serum albumin, 0.5 g/1 Tween-20) and incubated for l h at -h 37 °C. The colour reaction with a substrate 1.2-phenylenediamine dihydrochloride (Fluka Chemika, Basle, Switzerland) proceeded for 30 minutes (protected from the light), after which the reaction was halted with 2.5 mol/1 H 2 SO 4 . Absorbance at 492 nm was recorded using ELISA plate reader (läbsystems Multiscan MCC/340, Helsinki, Finland).
Markit-F LPL EIA Kit
The quantitation of lipoprotein lipase was performed according to the manufacturer's protocol (Markit-F LPL EIA Kit, Dainippon Pharmaceutical Co, Ltd., Osaka Japan) (15) . The assay is a onestep sandwich immunoassay kit that uses two distinct monoclonal antibodies specific for human lipoprotein lipase: One is an antilipoprotein lipase monoclonal antibody linked to a bacterial cell wall as an insolubilised monoclonal antibody, and the other is a ß-Z)-galactosidase labelled antibody as an enzyme-linked detecting monoclonal antibody. Lipoprotein lipase produced by THP-1 cells (human myelogenous leukaemia cells) is used as a standard. The fluorogenic substrate used is 4-methyl-umbelliferyl-ß-D-galactopyranoside. Fluorescence intensity was measured at an excitation of 365 nm and emission was measured at 450 nm using a Perkin Elmer LS-5 Luminescence Spectrometer, London, U. K.
Lipoprotein lipase activity assay
Lipoprotein lipase activity concentration was measured using the antiserum inhibition method (7).
Subjects
Sixty-six healthy Finns (38 women, 28 men) were studied. The mean age for women was 43 ± 6 years and the mean age for men 42 ± 8 years. The volunteers did not use any medication or oral contraceptives. Venous blood samples were drawn after an overnight fast. For lipoprotein lipase activity concentration and lipoprotein lipase mass concentration measurements, venous blood was drawn into chilled tubes containing lithium heparin 15 min after an intra-venous injection of heparin (100 lU/kg, Huhtamäki, Leiras, Helsinki, Finland). Postheparin plasma samples were stored at -70 °C before the measurements.
Statistical methods
Means, standard deviations (SD), and coefficients of variation (CV) were calculated for the lipoprotein lipase control samples. Pearson's correlation coefficients were calculated to evaluate the degree of linear association between variables, the significance of which was calculated using the paired /-test procedure.
Results
The purity of lipoprotein lipase
The purity of lipoprotein lipase was assessed on a 125 g/1 SDS-PAGE, as shown in figure 1A . Samples from the individual purification steps were analysed. The heparin-Sepharose chromatography was an efficient step for removing most of the proteins of human milk powder (fig. 1A, lane 2) . After heparin-Sepharose chromatography, the active lipoprotein lipase pool fractions from maminophenyl boronic acid agarose column contained a major contamination protein with a relative molecular weight of about 80000 (fig. 1A, lane 3) . Separate attempts were made to remove this protein using gel filtration, phenyl-Sepharose chromatography, and by using salt gradient (from 0.4 to 2 mol/1 NaCl) in heparinSepharose affinity chromatography, none of which were successful. Therefore, the lipoprotein lipase preparation obtained after the two affinity chromatography steps was concentrated and further purified using a preparative 125 g/1 SDS-PAGE. The final preparation contained a major band with a relative molecular weight of 58000, which was identified as lipoprotein lipase using monoclonal anti-lipoprotein lipase antibody in immunoblotting ( fig. IB) . This preparation was used as a calibrator standard in the ELISA system (see further: Standardisation of the ELISA method).
During the purification steps, it is possible that human milk lipoprotein lipase protein undergoes structural modifications that affect its immunoreactivity. According to the manufacturer's instructions, the lipoprotein lipase protein delivered in the Markit-F LPL EIA Kit (Dainippon Pharmaceutical C., Ltd. Osaka, Japan) has been produced in THP-1 leukaemia cells and has shown to be immunologically homologous with human postheparin plasma lipoprotein lipase (14) . It is, therefore, a good primary standard to calibrate other immunoassays for lipoprotein lipase mass determination. To determine the immunoreactive mass of our purified lipoprotein lipase, its protein concentration was measured by ELISA using the protein delivered as a primary standard in the Markit-F LPL EIA Kit.
Specificity of antihuman antibodies
The monoclonal antihuman lipoprotein lipase antibody produced by Oncogene Science has been tested by Babirak et al. (11) and has been shown to recognise an epitope present in the C-terminal part of human lipoprotein lipase (12) . Specific immunoreactivity of our affinitypurified polyclonal antihuman lipoprotein lipase antibody was tested with Western blot analysis. The affinitypurified antibody reacted with human lipoprotein lipase that was isolated from human milk or postheparin plasma, but it did not react with human hepatic lipase, another lipolytic enzyme released into the circulation by The validation of ELISA for lipoprotein lipase mass quantitation was examined by precision and sample dilution analysis. Postheparin plasma from five subjects was fractioned into aliquots of 100 μΐ before freezing and were stored at -70 °C. Five plasma samples were then analysed a total of ten times in the same assay (twice per week for five weeks) to calculate the assay precision. For inter-assay measurements, a new aliquot of postheparin plasma was thawed each time. The mean intra-assay and inter-assay coefficients of variation (CV) for the whole working range of the ELISA assay were 5.1% and 6.5%, respectively.
Dilution studies were carried out using five different postheparin plasma samples containing high, medium, and low mass concentrations of lipoprotein lipase. All samples were serially diluted ( curves were obtained within the range of standard lipoprotein lipase (0-70 μ£/1). The correlation of these measurements was good (r = 0.94 ± 0.04, mean ± SD).
Comparison of ELISA and commercial EIA assays
The correlation of the two methods was performed by analysing postheparin plasma samples with varying lipoprotein lipase concentrations. The regression between the two techniques has a correlation coefficient of 0.81, represented by the equation y = 2.58x + 51 ( fig. 3) . Accordingly, the correlation was good, although the ELISA method gave significantly higher values than the commercial one.
Lipoprotein lipase protein mass concentration and activity concentration in healthy subjects
Lipoprotein lipase activity concentrations and mass in postheparin plasma in healthy Finns were measured with ELISA and EIA (tab. 1). The values showed no significant differences between genders although women tended to have slightly higher levels. Differences in lipoprotein lipase concentration levels between the two assays is notable and will be discussed. plasma. The study describes the immunisation protocol of hens with semi-purified human milk lipoprotein lipase and purification of polyclonal anti-lipoprotein lipase antibodies. The monospecificity of the resulting polyclonal antibody was ascertained by the Western blotting technique.
Purifying of lipoprotein lipase enzyme to homogeneity presents certain problems. The content of lipoprotein lipase in human physiological sources is very low. The use of human milk as lipoprotein lipase enzyme source is justified since human milk is rich in lipoprotein lipase enzyme (18) . The heparin-Sepharose and w-aminophenylboronic acid agarose chromatographies were chosen for the purification steps. The selection was based on the studies by Uttsi-Oukari et al. (19) who showed these chromatographies to be preferential for purifying lipolytic enzymes from postheparin plasma. After the heparin-Sepharose affinity and w-aminophenylboronic acid agarose chromatographies the preparation of human milk lipoprotein lipase contained at least two proteins. This preparation is pure enough for immunisation purposes but cannot be used as a calibrator standard in the ELISA assay. Gel filtration, phenyl-Sepharose and the use of a salt gradient (from 0.4 to 2 mol/1 NaCl) in the heparin-Sepharose affinity chromatography failed to separate the lipoprotein lipase protein and contaminating protein present in the m-aminophenylboronic acid pool ( fig. 1, lane 3) . Preparative gel electrophoresis was therefore selected as the final purification method to produce the lipoprotein lipase standard for calibrating the ELISA method. The final preparation contained lipoprotein lipase protein, which reacted well with both polyclonal and monoclonal antihuman lipoprotein lipase antibodies.
Analytical ultracentrifiigation studies (26, 27 ) and a study using radiation inactivation (28) of purified lipoprotein lipase obtained from bovine milk indicated that the active lipoprotein lipase is a non-covalent homo-dimer glycoprotein (4). To measure total lipoprotein lipase mass concentration, including both monomeric and dimeric protein forms with immunological assays, either two different monoclonal antibodies or a combination of polyclonal and monoclonal antibodies is required. The present ELISA method uses a polyclonal antibody for capture and a monoclonal antibody as a detection antibody. Good sensitivity was achieved down to lipoprotein lipase mass concentrations of 10 \ig/l. The precision of the ELISA method was also good.
In the healthy Finnish subjects studied, there was a wide range of both lipoprotein lipase activity concentration and mass concentration in postheparin plasma. Both the ELISA method and a commercially available EIA kit for the quantitation of lipoprotein lipase mass concentration in plasma are sensitive; a good correlation existed between lipoprotein lipase activity concentration and mass concentration for both low and high values. The calculated specific activity (U/^g) is therefore uniform, and changes in this property can be used as a good tool to follow certain abnormalities in lipoprotein lipase metabolism.
The different levels in lipoprotein lipase mass concentrations found in two described methods may be due to the different antibodies and/or the primary standardisation of the assay. A relative good correlation between the two assays, however, suggests that the main contributor is a primary standardisation. Lipoprotein lipase protein in the samples, or in the primary or calibrator standards, may change its conformation during storage or thawing. This may have an major effect on the reactivity with anti-lipoprotein lipase antibodies and the shape of calibration curves. In all immunoassays using one or two different monoclonal anti-lipoprotein lipase antibodies, the reference values for postheparin plasma lipoprotein lipase in healthy individuals ranged from 200 to 400 μg/l (11, 12, 15) . The assays with a combination of affinitypurified polyclonal and monoclonal antibody, however, measure higher postheparin plasma lipoprotein lipase mass concentrations, the mean values being 800-1000 μg/l ((13), the present ELISA assay). In the previously described immunoassays (8) (9) (10) (11) (12) , the primary or calibrator standards were not described in detail, except in the method described by Ideda et al. (15) . In addition, the validation of these methods for lipoprotein lipase quantitation was poorly defined. At present, no international standards exist for lipoprotein lipase, which makes the comparison of results between different assays and laboratories impossible. Present standardisation efforts need to be directed toward removing sources of variability in laboratory methods through the use of certified reference material for calibration. For these reasons, a need for well-defined primary or calibrator standards and reference values is justified for studies in which lipoprotein lipase catalytic activity concentrations and mass concentrations are measured.
